Press Release Hub logo
  • Submit a Release
  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration

Contributed by: Business Wire

Logo

Business Wire logo

Tags

Science
Neurology
Other Science
Biotechnology
Research
Pharmaceutical
Health
Clinical Trials
Prothena Corporation plc

More Like This

Business Wire logo

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Business Wire logo

Prothena Reports Second Quarter 2024 Financial Results and Business Highlights

Business Wire logo

Prothena Reports Third Quarter 2023 Financial Results and Business Highlights

Business Wire logo

Prothena Reports First Quarter 2024 Financial Results and Business Highlights

Business Wire logo

Prothena to Participate in Upcoming Healthcare Conferences

Business Wire logo

Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

Business Wire logo

Prothena to Participate in Upcoming Healthcare Conferences

Business Wire logo

Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

Pages

  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

Press Release Hub

  • Our Services
  • Submit a Release

Websites

  • PA Media Group
  • PA Mediapoint
  • Distribution Packages

© PA Media Group. 2025

Terms of Use

Privacy Policy

Contact Us